Across 287 unique CTIS cell therapy trial codes covering 396 phase 1-3 trial-phase observations, CRO or CRO-like support vendors were listed in 75 trials, equal to 26.1% of the dataset. ICON / PRA was the most active named CRO group with 25 supported trials, followed by IQVIA with 20, Parexel with 17, PPD / Thermo Fisher with 13, and Syneos Health with 12. CRO need is strongest in operationally complex EU submissions: 34 of 45 trials spanning 4+ countries used CRO support, and 37 of 56 trials with 10+ sites used CRO support.
ICON / PRA appeared in 25 of 287 unique CTIS cell therapy trials, followed by IQVIA in 20, Parexel in 17, PPD / Thermo Fisher in 13, and Syneos Health in 12. Phase 2 is the strongest demand layer: 51 of 186 phase 2 trial memberships used CRO support, compared with 26 of 153 phase 1 and 25 of 57 phase 3 memberships.
Cell therapy CRO competition is concentrated but not monopolized. The top five CRO groups account for 87 named CRO-trial relationships across 75 CRO-supported trials, suggesting sponsors often combine global CROs with specialist vendors for EU submission, lab, data and supply-chain work.
CRO need rises sharply with European operational scale. Only 27 of 212 single-country trials used CRO support, but 34 of 45 trials with 4+ countries did. The same pattern appears for site capacity: 19 of 143 trials with 1-2 sites used CROs, compared with 37 of 56 trials with 10+ sites.
| Capacity band | CRO-supported | Share |
|---|---|---|
| 1 country | 27/212 | 12.7% |
| 2-3 countries | 14/30 | 46.7% |
| 4+ countries | 34/45 | 75.6% |
| 1-2 sites | 19/143 | 13.3% |
| 3-9 sites | 19/88 | 21.6% |
| 10+ sites | 37/56 | 66.1% |
| ≤20 participants | 24/136 | 17.6% |
| 21-60 participants | 25/91 | 27.5% |
| 61+ participants | 26/60 | 43.3% |
The strongest CRO trigger is not phase alone; it is EU execution complexity. CRO-supported trials averaged 4.0 countries, 15.1 sites and 71.3 participants, compared with 1.3 countries, 3.8 sites and 37.3 participants for trials without CRO support.
Oncology generated the largest absolute CRO workload, with CRO support in 33 of 119 oncology-tagged trials. Rare disease had the highest CRO intensity among major areas, with 21 of 38 trials supported by CROs, followed by neurology with 10 of 24 and immunology with 22 of 60.
The most attractive CRO opportunity is oncology-led but complexity-led: multiple myeloma alone had CRO support in 8 of 12 trials, while rare disease and neurology show higher CRO-use rates because specialist sites, small populations, biomarker work and CTIS country coordination are often bundled into the same submission.
The most common outsourced function was central lab, biomarker and bioanalytical testing, present in 81 of 287 trials and in 62 of 75 CRO-supported trials. EU/CTIS submission and regulatory correspondence appeared in 62 of 287 trials and 43 of 75 CRO-supported trials, making it one of the clearest commercial entry points for CROs supporting European cell therapy submissions.